Foghorn Therapeutics Inc.FHTXNASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank71
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-235.90%
↑ 92% vs avg
Percentile
P71
Within normal range
Streak
1 yr
Consecutive growthExpanding
Average
-3060.60%
Historical baseline
PeriodValueYoY Change
TTM-235.90%+45.1%
2024-429.90%-40.6%
2023-305.83%+48.3%
2022-591.93%+91.9%
2021-7292.42%+53.3%
2020-15628.84%-
20190.00%-
20180.00%-